KA/EN
Register
Medicines reference
Search
Search
Product

Xylazin bio

Favourites

Xylazine · Bioveta a.s.

1 form: solution. In force in Georgia: 1 of 1 (veterinary register).

Forms and doses1 of 1 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
2%, Solution · Cat Cat Sedation · Intramuscular / Subcutaneous: 1–2 mg/kgPremedication · Intramuscular: 0.5–1 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ქსილაზინი ბიო 2%
Verified on: 22 Oct 2026
2%, Solution · Dog Dog Sedation · Intramuscular: 1–2 mg/kgSedation · Intravenous: 0.5–1 mg/kgPremedication · Intramuscular: 1–2 mg/kg - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ქსილაზინი ბიო 2%
Verified on: 22 Oct 2026
Details: pack, label wording, sources, registration

Xylazin bio 2%, Solution

xylazine 20 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Label-concordant IM or IV sedation and IM anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures
6.7/10
Situational / acceptable
vetman assessment

Xylazin bio

2%, xylazine 20 mg/ml, solution for injection
Assessed clinical scopeDog · Label-concordant IM or IV sedation and IM anaesthetic premedication in appropriately selected dogs, with balanced analgesia for painful procedures · IM,IV
Care settingVeterinary-only administration after pre-anaesthetic assessment, exact weight/concentration/route calculation and independent double-check; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score 6.7/10 Situational / acceptable
Evidence confidence: Medium Georgia: Yes, veterinary · Verified on 22 Oct 2026

A useful authorised IM/IV canine sedative with clear exact dose rows, but substantial alpha-2 risk and incomplete analgesia keep it conditional and fully monitored.

Regulatory and scientific credibility7.5/10

The exact 50 ml presentation has current Georgian registration and a valid Romanian stand-alone authorisation with transparent formulation, dog routes and dose ranges. One-country EU breadth and limited exact-product outcomes cap credibility.

Clinical efficacy7.0/10

Established xylazine pharmacology and direct canine studies support reliable dose-dependent sedation; exact IM and IV options add flexibility. Response varies, modern protocols often prefer more selective alpha-2 agonists, and xylazine is not dependable stand-alone surgical analgesia.

Safety and tolerability5.0/10

Bradycardia/AV block, biphasic blood pressure, reduced cardiac output, arrhythmia, respiratory depression, emesis, temperature change, hyperglycaemia and rare arrest require strict selection and full monitoring. IV dosing demands particularly controlled titration.

Clinical practicality7.5/10

Single IM or titratable IV administration and a familiar concentration are operationally useful, with distinct protocol rows already available. Accurate small-volume measurement, fasting/airway planning, combination reconciliation and fully staffed monitoring/recovery remain substantial.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Use only after examination in a monitored veterinary setting. Record exact weight, 20 mg/ml concentration, route, protocol-specific dose, co-drugs and times; do not interchange the IM, IV or premedication rows.
  • Do not use with GI obstruction, significant cardiac disease/ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks.
  • Dog sedation is 1–2 mg/kg IM or 0.5–1 mg/kg IV once; ketamine premedication is a separate 1–2 mg/kg IM row. Use the lowest effective dose and never substitute one route/protocol range for another.
  • Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe; pressure may rise then fall while cardiac output decreases.
  • Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk.
  • Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect.
  • Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every component of ketamine protocols before administration.
  • Brachycephalic airway disease can cause life-threatening dyspnoea; deep-chested breeds may bloat. Pregnancy requires benefit–risk assessment and late-pregnancy use is contraindicated except at parturition.
  • Alpha-2 antagonism may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid, pain or co-anaesthetic risk. Calculate the reversal protocol and continue monitoring for haemodynamic change or re-sedation.
  • Prevent self-injection, ingestion and skin/eye/mucosal exposure; seek urgent medical advice after exposure and do not drive. Track opening/sterility of the multidose vial, store per label and do not use a contaminated or expired vial.
Assessment sources
  1. Xylazin bio Romanian SPC2021
  2. Xylazin bio exact2026
  3. Xylazin Rometar relation2026
  4. Xylexx VMD control2025
  5. AnaSed FDA control1992
  6. AAHA anaesthesia 20202020
  7. ACVAA monitoring 20252025
  8. Canine cardiopulmonary1975
  9. Canine xylazine ketamine1986
  10. Canine antagonism2009
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Label-concordant IM or SC sedation and IM anaesthetic premedication in appropriately selected cats, using the reconciled mg/kg dose and balanced analgesia
5.6/10
Weak evidence support
vetman assessment

Xylazin bio

2%, xylazine 20 mg/ml, solution for injection
Assessed clinical scopeCat · Label-concordant IM or SC sedation and IM anaesthetic premedication in appropriately selected cats, using the reconciled mg/kg dose and balanced analgesia · IM,SC
Care settingVeterinary-only administration after pre-anaesthetic assessment, exact weight/concentration/route calculation and independent double-check; airway, oxygen, cardiovascular/ventilation/temperature monitoring and supervised recovery immediately available
vetman score 5.6/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · Verified on 22 Oct 2026

The intended feline mg/kg regimen is pharmacologically plausible, but an official twofold volume contradiction creates a serious preventable dosing hazard and materially weakens the exact product.

Regulatory and scientific credibility6.5/10

The exact presentation is registered in Georgia and Romania with transparent formulation, but its official cat text contains a twofold conflict between 1–2 mg/kg and 0.1–0.2 ml/kg at 20 mg/ml. Reconciliation is possible, yet this material medication-error defect lowers exact-label credibility.

Clinical efficacy6.5/10

The valid exact authorisation and established alpha-2 effect support feline sedation, but modern direct feline outcomes are limited. The intended mg/kg range is plausible; efficacy does not validate the contradictory printed volume or make xylazine complete anaesthesia.

Safety and tolerability4.0/10

The same major alpha-2 cardiopulmonary, emetic, metabolic and reproductive hazards apply, while the label volume conflict could double the intended feline dose. Independent mg/kg-to-volume calculation and double-check are hard safety requirements, not optional clarification.

Clinical practicality5.5/10

A single IM/SC injection is physically simple, but the official twofold volume discrepancy makes routine use error-prone. Small-volume measurement, an independent calculation/double-check, vomiting/airway preparation, combination reconciliation and full recovery monitoring impose high clinical burden.

Full-course cost-effectiveness-

Current Georgian full-course price and vial-wastage data were unavailable; price is excluded from the denominator.

Important safety and use flags

  • Dosing conflict: use 1–2 mg/kg, which equals 0.05–0.1 ml/kg at 20 mg/ml. Do not use the Romanian SPC printed 0.1–0.2 ml/kg because it equals 2–4 mg/kg. Independently calculate and double-check before injection.
  • Do not use with GI obstruction, significant cardiac disease/ventricular arrhythmia, respiratory insufficiency, hepatic/renal impairment, seizure history, hypotension/shock or diabetes; avoid in puppies/kittens under six weeks.
  • Cat sedation is 1–2 mg/kg IM/SC once after resolving the volume conflict; ketamine premedication is a separate lower 0.5–1 mg/kg IM row. Do not merge these protocol doses or automatically repeat.
  • Monitor ECG/rhythm, heart rate, blood pressure, oxygenation, ventilation, temperature and sedation depth continuously through recovery. Bradycardia/AV block can be severe; pressure may rise then fall while cardiac output decreases.
  • Vomiting commonly occurs within minutes. Use an individual fasting plan, protect the airway and position/recover the patient to reduce regurgitation and aspiration risk; fasting does not eliminate that risk.
  • Xylazine alone is not reliable surgical analgesia or general anaesthesia. For painful procedures provide local/general anaesthesia and multimodal analgesia, reducing all interacting sedative/anaesthetic doses to effect.
  • Other CNS depressants are additive. Do not combine with epinephrine or other sympathomimetics because ventricular arrhythmia may follow; reconcile every component of ketamine protocols before administration.
  • Do not use in late pregnancy because uterine contraction and premature labour may occur; earlier pregnancy requires explicit benefit–risk assessment. Anticipate hyperglycaemia and polyuria.
  • Alpha-2 antagonism may reverse selected effects but does not erase aspiration, hypoxaemia, arrhythmia, temperature, fluid, pain or co-anaesthetic risk. Calculate the reversal protocol and continue monitoring for haemodynamic change or re-sedation.
  • Prevent self-injection, ingestion and skin/eye/mucosal exposure; seek urgent medical advice after exposure and do not drive. Track opening/sterility of the multidose vial, store per label and do not use a contaminated or expired vial.
Assessment sources
  1. Xylazin bio Romanian SPC2021
  2. Xylazin bio exact2026
  3. Xylazin Rometar relation2026
  4. Xylexx VMD control2025
  5. AnaSed FDA control1992
  6. AAHA anaesthesia 20202020
  7. ACVAA monitoring 20252025
  8. Feline metabolic effects2008
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Xylazine20 mg/ml
Formulation Type
Solution
Administration route
Intravenous, Intramuscular, Subcutaneous
Manufacturer
Bioveta a.s. · Czechia
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ქსილაზინი ბიო 2%
Verified on: 22 Oct 2026
 EU Yes, veterinary
№ 150180
Verified on: 22 Oct 2026
 UK No
Verified on: 22 Oct 2026
 US No
Verified on: 22 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 18 Oct 2026
Information not fully verified Veterinarian-administered sedation/premedication. Dog sedation: 1–2 mg/kg IM or 0.5–1 mg/kg IV once. Cat sedation: use 1–2 mg/kg IM/SC, which equals 0.05–0.1 ml/kg; reject the internally conflicting 0.1–0.2 ml/kg printed in the Romanian SPC. Separate ketamine-premedication rows are dog 1–2 mg/kg IM and cat 0.5–1 mg/kg IM. Independently calculate, double-check and monitor every dose.
Cat
WeightSedation · Intramuscular / SubcutaneousPremedication · Intramuscular
Any weight 1–2 mg/kg 0.5–1 mg/kg
  • Sedation · Intramuscular / Subcutaneous (once): Use the explicit 1–2 mg/kg figure: at 20 mg/ml this equals 0.05–0.1 ml/kg IM or SC once. The Romanian SPC also prints 0.1–0.2 ml/kg, which would equal 2–4 mg/kg and conflicts twofold; do not use that volume. Independently calculate and double-check before administration.
  • Premedication · Intramuscular (once): Premedication protocol dose: xylazine 0.5–1 mg/kg IM once with separately calculated atropine/ketamine under full anaesthetic monitoring. Do not substitute the higher sedation row or the internally conflicting printed cat volume.
Source:
Xylazin bio Romanian SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Xylazin bio 2% solution for injection - current Romanian authorisation and SPC
EU Veterinary Medicines Information / Romanian authority, 2021
Dog
WeightSedation · IntramuscularSedation · IntravenousPremedication · Intramuscular
Any weight 1–2 mg/kg 0.5–1 mg/kg 1–2 mg/kg
  • Sedation · Intramuscular (once): Dog sedation: 1–2 mg/kg IM once. Use the lowest effective dose after examination; fasting and anticholinergic use require a current patient/procedure-specific plan. Do not automatically repeat.
  • Sedation · Intravenous (once): Dog sedation: 0.5–1 mg/kg IV once, administered and titrated only by a veterinarian with full monitoring. Do not substitute the IM range or automatically repeat.
  • Premedication · Intramuscular (once): Dog premedication protocol dose: xylazine 1–2 mg/kg IM once with separately calculated atropine/ketamine under full anaesthetic monitoring. Reduce interacting drugs to effect and do not treat this as stand-alone anaesthesia.
Source:
Xylazin bio Romanian SPC
Official product label (SPC)
Approved by a medicines regulator as part of the product's authorisation. It applies to that product as authorised there.
Xylazin bio 2% solution for injection - current Romanian authorisation and SPC
EU Veterinary Medicines Information / Romanian authority, 2021

Known Contraindications

  • Critical
    Do not use in the last trimester of pregnancy (uterine contractions).
    Sources: Czech SPC
  • Critical
    Do not use with gastric dilatation or torsion or oesophageal obstruction.
    Sources: Czech SPC
  • Critical
    Dogs and cats: do not use with diabetes mellitus (xylazine raises blood glucose).
    Sources: Czech SPC
  • Critical
    Do not use if hypersensitive to xylazine or excipients.
    Sources: Czech SPC
  • Critical
    Dogs and cats: do not use in illness with vomiting. Do not combine with neuroleptics.
    Sources: Czech SPC
  • Warning
    Heart or circulatory disease: use with caution (Rometar); contraindicated in cardiopulmonary disease (Xylazin bio 2%).
    Sources: Czech SPC
  • Warning
    Respiratory disease: use with caution; contraindicated in cardiopulmonary disease (Xylazin bio 2%).
    Sources: Czech SPC
  • Caution
    Liver dysfunction: use with caution.
    Sources: Czech SPC
  • Caution
    Kidney dysfunction: use with caution.
    Sources: Czech SPC

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗